#

Novo Nordisk

: 101
Liver drugmaker Akero to be acquired by Novo Nordisk; shares soar 17%
News·
+1
·
Liver drugmaker Akero to be acquired by Novo Nordisk; shares soar 17%
Morgan Stanley gave one of the worst forecasts for Novo. What could bring down the stock?
News·
Morgan Stanley gave one of the worst forecasts for Novo. What could bring down the stock?
Pharma stocks in Europe reacted weakly to Trumps threats of new duties
News·
Pharma stocks in Europe reacted weakly to Trump's threats of new duties
Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?
News·
Novo drug outperformed its Eli Lilly counterpart in trials. Time to buy stock?
Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market
Small Caps·
Small caps that can challenge Novo Nordisk and Eli Lilly in the obesity drug market
The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?
News·
The oldest bank in Germany has bet on Novo Nordisk. How is it better than market favorite Eli Lilly?
Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?
News·
Novo Nordisk will cut 9,000 employees. Why do analysts believe the stock is up 60%?
Best-selling Novo reduces heart risks more effectively than competitor, trial shows
News·
Best-selling Novo reduces heart risks more effectively than competitor, trial shows
Wall Streets only bearish on Eli Lilly stock has changed its mind
News·
Wall Street's only bearish on Eli Lilly stock has changed its mind
Eli Lillys weight loss pill has passed one of the key phases of testing. Shares rose
News·
Eli Lilly's weight loss pill has passed one of the key phases of testing. Shares rose
Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?
News·
Viking shares fall 45% due to drug tests. Have the risks for Novo and Eli been reduced?
Morning in New York: foreign policy agenda remains in the center of attention of the markets
News·
Morning in New York: foreign policy agenda remains in the center of attention of the markets
Load more